Showing results (241-250 of 439) with videos related to
Sort By:
Pageof 44
BMJ Supportive & Palliative Care|July 19, 2020
Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burdenKathrin Sommer, Marco Vignetti, Francesco Cottone, et al.Oncotarget|May 19, 2018
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patientsMaria Rosaria Ricciardi, Valentina Salvestrini, Roberto Licchetta, et al.Journal of Hematology & Oncology|December 6, 2019
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paperSimona Soverini, Elisabetta Abruzzese, Monica Bocchia, et al.Cancer|June 22, 2011
Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drugRoberto Latagliata, Antonio Spadea, Michele Cedrone, et al.Annals of Hematology|October 1, 2016
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinionMassimo Breccia, Patrizia Pregno, Paolo Spallarossa, et al.Frontiers in Oncology|December 4, 2025
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologistsMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.Journal of Clinical Epidemiology|March 23, 2021
The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3LEva M Gamper, Francesco Cottone, Kathrin Sommer, et al.Critical Reviews in Oncology/Hematology|January 11, 2014
Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013Massimo Breccia, Giuliana Alimena, Michele Baccarani, et al.Leukemia & Lymphoma|September 15, 2021
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)Paola Guglielmelli, Francesca Palandri, Carmine Selleri, et al.Annals of Hematology|October 22, 2024
Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trialFabio Efficace, Francesco Sparano, Massimo Breccia, et al.Pageof 44